{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T18:40:00Z","timestamp":1792780800684,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82570707"],"award-info":[{"award-number":["82570707"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Major Science and Technology innovation Project of Fujian Province","award":["2023Y9269"],"award-info":[{"award-number":["2023Y9269"]}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2023J01239"],"award-info":[{"award-number":["2023J01239"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-026-03254-7","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T13:45:50Z","timestamp":1785159950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of Tenofovir disoproxil fumarate (TDF) or Entecavir (ETV) combined with interferon for the treatment of chronic hepatitis B: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Shuqi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huatang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"6","key":"3254_CR1","first-page":"1425","volume":"11","author":"H You","year":"2023","unstructured":"You H, Wang F, Li T, Xu X, Sun Y, Nan Y, et al. Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022). J Clin Transl Hepatol. 2023;11(6):1425\u201342.","journal-title":"J Clin Transl Hepatol"},{"key":"3254_CR2","doi-asserted-by":"crossref","unstructured":"Zhou J, Wu X, Wei W, You H, Jia J, Kong Y. A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B. Int J Environ Res Public Health. 2016;13(5):730.","DOI":"10.3390\/ijerph13070730"},{"issue":"7","key":"3254_CR3","doi-asserted-by":"publisher","first-page":"e0132219","DOI":"10.1371\/journal.pone.0132219","volume":"10","author":"QL Xie","year":"2015","unstructured":"Xie QL, Zhu Y, Wu LH, Fu LL, Xiang Y. The Efficacy and Safety of Entecavir and Interferon Combination Therapy for Chronic Hepatitis B Virus Infection: A Meta-Analysis. PLoS ONE. 2015;10(7):e0132219.","journal-title":"PLoS ONE"},{"issue":"5","key":"3254_CR4","doi-asserted-by":"publisher","first-page":"e0269424","DOI":"10.1128\/spectrum.02694-24","volume":"13","author":"H Liang","year":"2025","unstructured":"Liang H, Zheng X, Mao Q, Yang J, Ruan Q, Wu C, et al. Comparative efficacy and safety of pegylated interferon-alpha monotherapy vs combination therapies with entecavir or tenofovir in chronic hepatitis B patients. Microbiol Spectr. 2025;13(5):e0269424.","journal-title":"Microbiol Spectr"},{"issue":"1","key":"3254_CR5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","volume":"150","author":"P Marcellin","year":"2016","unstructured":"Marcellin P, Ahn SH, Ma X, Caruntu FA, Tak WY, Elkashab M, et al. Combination of Tenofovir Disoproxil Fumarate and Peginterferon \u03b1-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. Gastroenterology. 2016;150(1):134\u2013e4410.","journal-title":"Gastroenterology"},{"issue":"12","key":"3254_CR6","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jiac.2020.07.005","volume":"26","author":"M Bahardoust","year":"2020","unstructured":"Bahardoust M, Mokhtare M, Barati M, Bagheri-Hosseinabadi Z, Karimi Behnagh A, Keyvani H, et al. A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: A 48-week follow-up study. J Infect Chemother. 2020;26(12):1265\u201371.","journal-title":"J Infect Chemother"},{"issue":"10","key":"3254_CR7","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1111\/jvh.13571","volume":"28","author":"J Li","year":"2021","unstructured":"Li J, Qu L, Sun X, Liu Y, Gong Q, Yu D, et al. Peg-interferon alpha add-on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg-positive chronic hepatitis B na\u00efve patients. J Viral Hepat. 2021;28(10):1381\u201391.","journal-title":"J Viral Hepat"},{"issue":"5","key":"3254_CR8","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1002\/hep.27586","volume":"61","author":"WP Brouwer","year":"2015","unstructured":"Brouwer WP, Xie Q, Sonneveld MJ, Zhang N, Zhang Q, Tabak F, et al. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study). Hepatology. 2015;61(5):1512\u201322.","journal-title":"Hepatology"},{"issue":"12","key":"3254_CR9","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1093\/cid\/ciu702","volume":"59","author":"Q Xie","year":"2014","unstructured":"Xie Q, Zhou H, Bai X, Wu S, Chen JJ, Sheng J, et al. A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B e antigen-positive chronic hepatitis B. Clin Infect Dis. 2014;59(12):1714\u201323.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"3254_CR10","doi-asserted-by":"publisher","first-page":"190","DOI":"10.4103\/sjg.SJG_541_16","volume":"23","author":"H Al Ashgar","year":"2017","unstructured":"Al Ashgar H, Peedikayil MC, Al Quaiz M, Al Sohaibani F, Al Fadda A, Khan MQ, et al. HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study. Saudi J Gastroenterol. 2017;23(3):190\u20138.","journal-title":"Saudi J Gastroenterol"},{"issue":"4","key":"3254_CR11","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/apt.15098","volume":"49","author":"KS Liem","year":"2019","unstructured":"Liem KS, van Campenhout MJH, Xie Q, Brouwer WP, Chi H, Qi X, et al. Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B. Aliment Pharmacol Ther. 2019;49(4):448\u201356.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"3254_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/jvh.12467","volume":"23","author":"P Tangkijvanich","year":"2016","unstructured":"Tangkijvanich P, Chittmittraprap S, Poovorawan K, Limothai U, Khlaiphuengsin A, Chuaypen N, et al. A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response. J Viral Hepat. 2016;23(6):427\u201338.","journal-title":"J Viral Hepat"},{"issue":"14","key":"3254_CR13","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1097\/CM9.0000000000000857","volume":"133","author":"JM Yang","year":"2020","unstructured":"Yang JM, Chen LP, Wang YJ, Lyu B, Zhao H, Shang ZY, et al. Entecavir add-on Peg-interferon therapy plays a positive role in reversing hepatic fibrosis in treatment-na\u00efve chronic hepatitis B patients: a prospective and randomized controlled trial. Chin Med J (Engl). 2020;133(14):1639\u201348.","journal-title":"Chin Med J (Engl)"},{"issue":"14","key":"3254_CR14","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.4103\/0366-6999.235880","volume":"131","author":"DW Jun","year":"2018","unstructured":"Jun DW, Ahn SB, Kim TY, Sohn JH, Kim SG, Lee SW, et al. Efficacy of Pegylated Interferon Monotherapy versus Sequential Therapy of Entecavir and Pegylated Interferon in Hepatitis B e Antigen-Positive Hepatitis B Patients: A Randomized, Multicenter, Phase IIIb Open-Label Study (POTENT Study). Chin Med J (Engl). 2018;131(14):1645\u201351.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"3254_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12876-017-0657-y","volume":"17","author":"Y Xu","year":"2017","unstructured":"Xu Y, Wang X, Liu Z, Zhou C, Qi W, Jiao J, et al. Addition of nucleoside analogues to peg-IFN\u03b1-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFN\u03b1-2a: a randomized controlled trial. BMC Gastroenterol. 2017;17(1):102.","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"3254_CR16","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s12072-021-10162-1","volume":"15","author":"S Chen","year":"2021","unstructured":"Chen S, Zhou J, Wu X, Meng T, Wang B, Liu H, et al. Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B. Hepatol Int. 2021;15(3):611\u201320.","journal-title":"Hepatol Int"},{"issue":"3","key":"3254_CR17","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.clinthera.2020.12.022","volume":"43","author":"C Hu","year":"2021","unstructured":"Hu C, Song Y, Tang C, Li M, Liu J, Liu J, et al. Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: A Real-world Experience. Clin Ther. 2021;43(3):572\u2013e813.","journal-title":"Clin Ther"},{"issue":"4","key":"3254_CR18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/jvh.12820","volume":"25","author":"ES Cannizzo","year":"2018","unstructured":"Cannizzo ES, Tincati C, Binda F, Ronzi P, Cazzaniga FA, Antinori S, et al. Unconventional T cells in chronic hepatitis B patients on long-term suppressive therapy with tenofovir followed by a Peg-IFN add-on strategy: A randomized study. J Viral Hepat. 2018;25(4):381\u201390.","journal-title":"J Viral Hepat"},{"issue":"12","key":"3254_CR19","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1007\/s10620-018-5251-9","volume":"63","author":"SH Ahn","year":"2018","unstructured":"Ahn SH, Marcellin P, Ma X, Caruntu FA, Tak WY, Elkhashab M, et al. Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis. Dig Dis Sci. 2018;63(12):3487\u201397.","journal-title":"Dig Dis Sci"},{"key":"3254_CR20","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva: World Health Organization \u00a9 World Health Organization 2024.; 2024."},{"issue":"1","key":"3254_CR21","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1186\/s12879-021-06554-1","volume":"21","author":"J Shang","year":"2021","unstructured":"Shang J, Zhou J, Liu H, Ise RM, Tu Y, Ran J, et al. Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients. BMC Infect Dis. 2021;21(1):912.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"3254_CR22","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/gutjnl-2016-312653","volume":"67","author":"K Murata","year":"2018","unstructured":"Murata K, Asano M, Matsumoto A, Sugiyama M, Nishida N, Tanaka E, et al. Induction of IFN-\u03bb3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. Gut. 2018;67(2):362\u201371.","journal-title":"Gut"},{"issue":"8","key":"3254_CR23","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/intimm\/dxaa018","volume":"32","author":"Y Yamamoto","year":"2020","unstructured":"Yamamoto Y, Kakizaki M, Shimizu T, Carreras J, Chiba T, Chamoto K, et al. PD-L1 is induced on the hepatocyte surface via CKLF-like MARVEL transmembrane domain-containing protein 6 up-regulation by the anti-HBV drug Entecavir. Int Immunol. 2020;32(8):519\u201331.","journal-title":"Int Immunol"},{"issue":"11","key":"3254_CR24","doi-asserted-by":"publisher","first-page":"5475","DOI":"10.1002\/jmv.28003","volume":"94","author":"J Lian","year":"2022","unstructured":"Lian J, Kuang W, Jia H, Lu Y, Zhang X, Ye C, et al. Pegylated interferon-\u03b1-2b combined with tenofovir disoproxil fumarate, granulocyte-macrophage colony-stimulating factor, and hepatitis B vaccine treatment for na\u00efve HBeAg-positive chronic hepatitis B patients: A prospective, multicenter, randomized controlled study. J Med Virol. 2022;94(11):5475\u201383.","journal-title":"J Med Virol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-026-03254-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03254-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03254-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T18:02:35Z","timestamp":1792778555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-026-03254-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3254"],"URL":"https:\/\/doi.org\/10.1186\/s12985-026-03254-7","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study is a meta-analysis of previously published studies.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is a meta-analysis of previously published studies, and all data used are publicly available.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"246"}}